Tigenix (TIG) Earns Daily News Sentiment Score of 0.35
Media stories about Tigenix (NASDAQ:TIG) have been trending positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tigenix earned a news sentiment score of 0.35 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.0802580998027 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Tigenix (TIG) Upgraded to “Hold” by Zacks Investment Research (americanbankingnews.com)
- BRIEF-Tigenix Plans To Focus On Its eASC Platform And Product Candidates Cx601 And Cx611 (reuters.com)
- Tigenix’s (TIG) “Buy” Rating Reaffirmed at Canaccord Genuity (americanbankingnews.com)
- Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn’s disease – BioWorld Online (bioworld.com)
- Tigenix (TIG) Given a $30.00 Price Target at Canaccord Genuity (americanbankingnews.com)
A number of brokerages recently commented on TIG. Canaccord Genuity set a $30.00 price target on Tigenix and gave the stock a “buy” rating in a report on Tuesday, December 12th. Zacks Investment Research upgraded Tigenix from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, BidaskClub lowered Tigenix from a “sell” rating to a “strong sell” rating in a report on Saturday, December 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Tigenix currently has a consensus rating of “Hold” and an average price target of $34.50.
Tigenix Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Receive News & Ratings for Tigenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tigenix and related companies with MarketBeat.com's FREE daily email newsletter.